Data gathered: April 15
AI Stock Analysis - Codexis (CDXS)
Analysis generated February 29, 2024. Powered by Chat GPT.
Codexis specializes in the development of enzymes for a broad range of applications, including pharmaceutical production, biofuel manufacturing, and industrial processes. The company leverages its proprietary technology platform to discover, develop, and produce highly optimized proteins. Enzymes, as biocatalysts, are central to green chemistry initiatives because they often require milder conditions and generate less waste than traditional synthetic methods.
Stock Alerts - Codexis (CDXS)
 |
Codexis | April 10 Price is down by -5.6% in the last 24h. |
|
Codexis | April 10 Insider Alert: Opaleye Management Inc. is buying shares |
|
Codexis | April 9 Price is up by 7.4% in the last 24h. |
|
Codexis | April 7 Price is down by -7.3% in the last 24h. |
Alternative Data for Codexis
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 7 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | 31 | Sign up | Sign up | Sign up |
| Patents | 304 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 11,332 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,170 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,658 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 50 | Sign up | Sign up | Sign up |
| Linkedin Employees | 256 | Sign up | Sign up | Sign up |
About Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics.
| Price | $2.30 |
| Target Price | Sign up |
| Volume | 506,590 |
| Market Cap | $195M |
| Year Range | $1.97 - $5.81 |
| Dividend Yield | 0% |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
Protein Engineering Market Competitive Landscape Report 2025, with Bruker, Codexis, Danaher, Thermo Fisher Scientific and GenScriptApril 14 - GlobeNewswire |
|
Codexis Announces Byron Dorgan to Retire from Board of DirectorsApril 9 - Finnhub |
|
 |
Codexis Appoints Cynthia Collins to Board of DirectorsMarch 31 - Yahoo |
Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing ServicesMarch 23 - Finnhub |
|
 |
Cantor Fitzgerald Reduces Earnings Estimates for CodexisMarch 13 - ETF Daily News |
|
Codexis, Inc. (NASDAQ:CDXS) Shares Bought by Rhumbline AdvisersMarch 9 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 13M | 18M | -5.1M | -21M | -14M | -0.290 |
| Q2 '24 | 8M | 19M | -11M | -23M | -21M | -0.320 |
| Q1 '24 | 17M | 18M | -720,000 | -12M | -9.9M | -0.160 |
| Q4 '23 | 27M | 13M | 14M | -7.2M | 2.3M | -0.100 |
| Q3 '23 | 9.3M | 19M | -9.9M | -35M | -5.8M | -0.500 |
Insider Transactions View All
| Opaleye Management Inc. filed to buy 9,465,000 shares at $2. April 9 '25 |
| Opaleye Management Inc. filed to buy 9,365,000 shares at $2.3. April 3 '25 |
| Opaleye Management Inc. filed to buy 9,290,000 shares at $2.5. April 3 '25 |
| Opaleye Management Inc. filed to buy 9,285,000 shares at $2.5. April 3 '25 |
| Opaleye Management Inc. filed to buy 9,250,000 shares at $2.5. March 24 '25 |
Similar companies
Read more about Codexis (CDXS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Codexis?
The Market Cap of Codexis is $195M.
What is the current stock price of Codexis?
Currently, the price of one share of Codexis stock is $2.30.
How can I analyze the CDXS stock price chart for investment decisions?
The CDXS stock price chart above provides a comprehensive visual representation of Codexis' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Codexis shares. Our platform offers an up-to-date CDXS stock price chart, along with technical data analysis and alternative data insights.
Does CDXS offer dividends to its shareholders?
As of our latest update, Codexis (CDXS) does not offer dividends to its shareholders. Investors interested in Codexis should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Codexis?
Some of the similar stocks of Codexis are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.